Search

everythinglearnresearchcommunity

for

Search:↓

Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.

Baricitinib improved platelet counts and alopecia in a 16-year-old with chronic immune thrombocytopenia.

BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.

CAP1/Prss8 does not activate PAR2 or inhibit PN-1.

The new drug carriers show promise for better targeting and treating ovarian cancer.

A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.

Baricitinib effectively reduces hair loss in severe alopecia areata with mild side effects.

Continued ritlecitinib treatment can lead to hair regrowth in some patients with alopecia areata who initially don't respond.

Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.

Baricitinib significantly improved hair regrowth and quality of life in severe alopecia areata patients.

Baricitinib was effective and safe for severe hair loss treatment over 6 months.

The rash resolved after stopping ponatinib.

Baricitinib shows promise for severe alopecia areata but isn't a cure and has side effects.

PROTACs show promise in cancer treatment by effectively degrading specific harmful proteins.

CS-891 may effectively treat hair loss by blocking enzymes in hair follicles.

Small molecules KY19382 and KY19334 may help treat skin cancer by reducing CDK1 levels and blocking harmful cell signals.

A KLK5 inhibitor effectively improved skin symptoms in a mouse model of Netherton Syndrome.

Clascoterone cream was approved in the USA for treating acne in people aged 12 and older.

Low-dose sorafenib can cause severe facial acne, treatable with topical medication.

Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.

Drugs targeting EMT molecules show promise for treating lichen planopilaris.

Patients were very satisfied with hair regrowth after taking ritlecitinib for alopecia areata.

Glycyrrhizic acid may help reduce unwanted hair growth.

Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.

Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.

Telitacicept effectively improved hair regrowth in a woman with lupus and alopecia.

ISCK03 stops melanin production in human melanoma cells and lightens skin color in mice and guinea pigs.

AP collagen peptides help hair grow and improve hair health.

Baricitinib effectively promotes regrowth of eyebrows and eyelashes in alopecia areata patients.